Namu Med

Namu Med Sales Division is a for-profit sole proprietorship headquartered in Songpa District, Seoul, South Korea, and registered in the System for Award Management (SAM.gov) since August 2017. The entity specializes exclusively in providing biochemical reagents and testing supplies for antibiotic susceptibility testing to support U.S. military medical laboratories and research programs. Namu Med has established itself as a critical supplier to the Defense Health Agency, with a proven track record of consistent performance in delivering specialized microbiological testing materials that support the medical readiness and health surveillance of U.S. military personnel.

Namu Med has received multiple firm fixed-price delivery order contracts from the Defense Health Agency for the provision of reagents used in biochemical antibiotic susceptibility testing. These delivery orders, which have ranged in value from $5,269.18 to $54,883.20, have supported U.S. military medical facilities in South Korea, particularly the Brian Allgood Army Community Hospital. The specific products supplied include plate trypticase soy agar and other biochemical testing reagents essential for microbiological analysis and antibiotic resistance monitoring. All delivery order contracts have been awarded without set-aside designations, indicating that Namu Med competes openly in the federal marketplace. The contracts are executed under an overarching indefinite delivery contract vehicle, which allows the Defense Health Agency to issue task orders on an as-needed basis. Performance for all contracts occurs at the place of performance in South Korea, supporting U.S. Forces Korea personnel and military medical command operations.

Namu Med holds a single-award indefinite delivery contract with the Defense Health Agency valued at $1,073,259.72, awarded on October 1, 2022, with an ultimate completion date of September 30, 2027. This contract establishes a base year plus four option years for the procurement of reagents for biochemical antibiotic susceptibility testing and includes specific products such as plate trypticase soy agar and related supplies supporting antibiotic susceptibility testing protocols. The indefinite delivery contract structure enables the Defense Health Agency to procure critical medical testing supplies through multiple task orders executed under the overarching contract authority, ensuring continued availability of specialized reagents for military medical laboratory operations. Under this contract vehicle, Namu Med has received task orders ranging from approximately $5,000 to $68,000, with performance periods aligned to fiscal and operational timelines. All task orders maintain firm fixed-price structures with no set-aside provisions, and no sub-award partners have been identified. The indefinite delivery contract demonstrates the Defense Health Agency's continued reliance on Namu Med's specialized testing materials and reflects the agency's procurement flexibility to obtain critical medical supplies through multiple task orders supporting military medical facilities operating overseas.